Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine's Effect on Anhedonia and Anxiety in Depression Using 7T MRI
NCT06213324Phase 4Active, not recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Jan 2024
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ketamine in major depressive disorder (MDD), sponsored by Icahn School of Medicine at Mount Sinai. Started Jan 2024; status: active, not recruiting.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06213324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06213324.